Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial

Phase 3positivePBHPositive

AI Analysis

Summary

Amylyx's PBH drug, acquired from Eiger BioPharmaceuticals for $35 million during bankruptcy proceedings in 2024, has met endpoints in its Phase III trial.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

met endpoints

Importance:7/10

Sentiment:

0.80

Phase 3Positive DataM&ABankruptcyEndpoint Met

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 19, 2026 10:12 AM

Read Original